In a research report released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Repros Therapeutics Inc (NASDAQ:RPRX) with a …
Brean Capital’s healthcare analyst Jonathan Aschoff weighed in with a negative view on Rockwell Medical Inc (NASDAQ:RMTI), reiterating a Sell rating on the stock, with a $4.00 price …
In a research report released Monday, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Heron Therapeutics Inc (NASDAQ:HRTX) and raised the …
In a research report issued today, Brean Capital analyst Jonathan Aschoff offered some commentary on Regeneron Pharmaceuticals Inc (NASDAQ:REGN), following the news that Regeneron’s Praluent, the …
Brean Capital analyst Jonathan Aschoff came out today with some commentary on OHR Pharmaceutical Inc (NASDAQ:OHRP), after the company reported initial, encouraging data for the treatment of …
On June 22, Brean Capital analyst Jonathan Aschoff weighed in on Keryx Biopharmaceuticals (NASDAQ:KERX) and Rockwell Medical Inc (NASDAQ:RMTI) to provide commentary on …
Brean Capital analyst Jonathan Aschoff came out with a favorable report on Recro Pharma Inc (NASDAQ:REPH) following several investor meetings with the company’s management. …
In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) with a $525 price target, …
Heron Therapeutics Inc (NASDAQ:HRTX) shares have taken off, adding 60% to trade at $19.76, following the news that the company’s late-stage study of its treatment for chemotherapy-induced nausea and …
Brean Capital analyst Jonathan Aschoff came out today with a few insights on Cytosorbents Corp (NASDAQ:CTSO), after the company released its first-quarter results last week. …
